Source BioScience PLC Form 8.3 - Source BioScience plc - Amendment (1703I)
25 Agosto 2016 - 10:30AM
UK Regulatory
TIDMSBS
RNS Number : 1703I
Source BioScience PLC
25 August 2016
AMMENT TO RULE 8.3 DISCLOSURE SUBMITTED ON 11 AUGUST 2016 AND
REPLACEMENT FOR RULE 8.3 DISCLOSURES SUBMITTED ON 28 JULY 2016 AND
2 AUGUST 2016
PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY PERSONS
WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
Rule 8.3 of the Takeover Code (the "Code")
1. KEY INFORMATION
(a) Full name of discloser: Richard Griffiths and Cream Capital Limited controlled
undertaking.
---------------------------------------------------------- ----------------------------------------------------------
(b) Owner or controller of interests and short positions N/A
disclosed, if different from 1(a):
The naming of nominee or vehicle companies is
insufficient. For a trust, the trustee(s),
settlor and beneficiaries must be named.
---------------------------------------------------------- ----------------------------------------------------------
(c) Name of offeree in relation to whose relevant Source BioScience Plc
securities this form relates:
Use a separate form for each offeree
---------------------------------------------------------- ----------------------------------------------------------
(d) If an exempt fund manager connected with an offeree, N/A
state this and specify identity of
offeree:
---------------------------------------------------------- ----------------------------------------------------------
(e) Date position held/dealing undertaken: Dealing disclosure - 11 August 2016
For an opening position disclosure, state the latest
practicable date prior to the disclosure
---------------------------------------------------------- ----------------------------------------------------------
(f) In addition to the company in 1(c) above, is the No
discloser making disclosures in respect
of any other party to the offer?
If it is a cash offer or possible cash offer, state "N/A"
---------------------------------------------------------- ----------------------------------------------------------
2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE
If there are positions or rights to subscribe to disclose in
more than one class of relevant securities of the offeror or
offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for
each additional class of relevant security.
(a) Interests and short positions in the relevant securities of
the offeror or offeree to which the disclosure relates following
the dealing (if any)
Class of relevant security: 2p ordinary
------------------------------------------------------------------------- -------------------------------------------
Interests Short positions
------------------------------------------------------------------------- ----------------------- ------------------
Number % Number %
------------------------------------------------------------------------- -------------- ------- ------------- ---
(1) Relevant securities owned and/or controlled: Ordinary Shares
GB0009739649 7,050,000 2.02
------------------------------------------------------------------------- -------------- ------- ------------- ---
(2) Cash-settled derivatives:
------------------------------------------------------------------------- -------------- ------- ------------- ---
(3) Stock-settled derivatives (including options) and agreements to
purchase/sell:
------------------------------------------------------------------------- -------------- ------- ------------- ---
TOTAL: 7,050,000 2.02
------------------------------------------------------------------------- -------------- ------- ------------- ---
All interests and all short positions should be disclosed.
Details of any open stock-settled derivative positions
(including traded options), or agreements to purchase or sell
relevant securities, should be given on a Supplemental Form 8 (Open
Positions).
(b) Rights to subscribe for new securities (including directors' and other employee options)
Class of relevant security in relation to which subscription right exists: N/A
---------------------------------------------------------------------------- ----
Details, including nature of the rights concerned and relevant percentages:
---------------------------------------------------------------------------- ----
3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE
Where there have been dealings in more than one class of
relevant securities of the offeror or offeree named in 1(c), copy
table 3(a), (b), (c) or (d) (as appropriate) for each additional
class of relevant security dealt in.
The currency of all prices and other monetary amounts should be
stated.
(a) Purchases and sales
Class of relevant security Purchase/sale Number of securities Price per unit
---------------------------- --------------- --------------------- ---------------
Ordinary Purchase 400,000 17.72p
---------------------------- --------------- --------------------- ---------------
In addition to the above purchase on 11 August 2016, additional
dealings were made between the dates of 6 July 2016 and 10 August
2016 as detailed in the additional dealing table attached at the
end of this disclosure.
(b) Cash-settled derivative transactions
Class of relevant Product description Nature of dealing Number of reference Price per unit
security e.g. CFD e.g. opening/closing a securities
long/short position,
increasing/reducing a
long/short position
------------------------- -------------------- ------------------------- ------------------------- ---------------
(c) Stock-settled derivative transactions (including options)
(i) Writing, selling, purchasing or varying
Class of Product Writing, Number of Exercise Type Expiry date Option money
relevant description purchasing, securities price per e.g. paid/
security e.g. call selling, to which unit American, received per
option varying etc. option European unit
relates etc.
------------- ------------- ------------- ------------- -------------- ------------- ------------ -------------
(ii) Exercise
Class of relevant Product description Exercising/ exercised Number of securities Exercise price per
security e.g. call option against unit
----------------------- -------------------- ----------------------- --------------------- -----------------------
(d) Other dealings (including subscribing for new securities)
Class of relevant security Nature of dealing Details Price per unit (if applicable)
e.g. subscription, conversion
--------------------------- ------------------------------- -------- -------------------------------
4. OTHER INFORMATION
(a) Indemnity and other dealing arrangements
Details of any indemnity or option arrangement, or any agreement or understanding, formal
or informal, relating to relevant securities which may be an inducement to deal or refrain
from dealing entered into by the person making the disclosure and any party to the offer or
any person acting in concert with a party to the offer:
Irrevocable commitments and letters of intent should not be included. If there are no such
agreements, arrangements or understandings, state "none"
---------------------------------------------------------------------------------------------
None
---------------------------------------------------------------------------------------------
(b) Agreements, arrangements or understandings relating to options or derivatives
Details of any agreement, arrangement or understanding, formal or informal, between the person
making the disclosure and any other person relating to:
(i) the voting rights of any relevant securities under any option; or
(ii) the voting rights or future acquisition or disposal of any relevant securities to which
any derivative is referenced:
If there are no such agreements, arrangements or understandings, state "none"
-----------------------------------------------------------------------------------------------
None
-----------------------------------------------------------------------------------------------
(c) Attachments
Is a Supplemental Form 8 (Open Positions) attached? No
---------------------------------------------------- ---
Date of disclosure: 25 August 2016
--------------------- ----------------
Contact name: James Sutcliffe
--------------------- ----------------
Telephone number: 01534 719761
--------------------- ----------------
Public disclosures under Rule 8 of the Code must be made to a
Regulatory Information Service and must also be emailed to the
Takeover Panel at monitoring@disclosure.org.uk. The Panel's Market
Surveillance Unit is available for consultation in relation to the
Code's disclosure requirements on +44 (0)20 7638 0129.
The Code can be viewed on the Panel's website at
www.thetakeoverpanel.org.uk.
(a) Purchases and sales
Class
of relevant No. of
Date securities securities Price Transaction % Held
---------- -------------- ------------ ------ ------------ -------
06/07/16 Ordinary 250,000 17.65 Purchase 1.00%
12/07/16 Ordinary 100,000 17.88 Purchase 1.03%
22/07/16 Ordinary 500,000 17.88 Purchase 1.17%
25/07/16 Ordinary 200,000 17.87 Purchase 1.23%
28/07/16 Ordinary 750,000 17.75 Purchase 1.45%
02/08/16 Ordinary 750,000 17.88 Purchase 1.66%
10/08/16 Ordinary 850,000 17.87 Purchase 1.90%
---------- -------------- ------------ ------ ------------ -------
(b) Cash-settled derivative transactions
Class of relevant Product description Nature of dealing Number of reference Price per unit
security e.g. CFD e.g. opening/closing a securities
long/short position,
increasing/reducing a
long/short position
------------------------- -------------------- ------------------------- ------------------------- ---------------
18/07/16 Spread Bet Open position 300,000 17.884p
02/08/16 Spread Bet Increase position 300,000 17.785p
04/08/16 Spread Bet Increase position 250,000 17.885p
10/08/16 Spread Bet Closure of position (850,000) 17.75p
------------------------- -------------------- ------------------------- ------------------------- ---------------
This information is provided by RNS
The company news service from the London Stock Exchange
END
RETUVUORNWAWUAR
(END) Dow Jones Newswires
August 25, 2016 09:30 ET (13:30 GMT)
Source Bioscience (LSE:SBS)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Source Bioscience (LSE:SBS)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024